CB001 bioactive compounds improve intestinal immune disorders caused by simulated microgravity and radiation through anti-inflammatory

Gastrointestinal discomfort is one of the most common issues during spaceflight, and there is currently a lack of targeted drug treatment strategies. Current research in this area focuses on single-factor modeling, lacking a comprehensive understanding. In the present study, we constructed space flight models based on most important two factors, microgravity and low-dose radiation. Histological, cellular and molecular analyses confirmed the advantage of this dual-factor model in simulating space flight-caused injuries. Upregulated inflammatory and homeostasis disruption were observed in intestines treated by these dual factors. Our data revealed that dual factors enhanced the migration of a Ccr7+ B cells into intestines through upregulating the expression of Cxcr4, which exerted strong activation regulations on leukocytes. We further validated that bioactive compounds of CB001 effectively alleviated intestinal perturbations through recovering the expression of tight junction proteins, suppressing the migration of B cells and downregulating the levels of pro-inflammatory cytokines. Collectively, our work offered CB001 compounds as candidate intervention drug for space flight-induced intestine dysfunctions based on a dual-factor mice model. These data shed lights on special medicine screening for health protection in space flight.